Navigation Links
A Broad-Spectrum Antibiotic with Activity Against MRSA and Pseudomonas Aeruginosa Would Earn a Higher Patient Share in the U.S. than in Europe for the Treatment of Hospital-Acquired Pneumonia
Date:3/3/2009

Merck's Drug Will Remain Decision Resources Gold Standard Through 2017, According to a New Report from Decision Resources

WALTHAM, Mass., March 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a broad-spectrum intravenous antibiotic that has activity against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), shows higher efficacy than the current benchmark (Wyeth's Zosyn/Tazocin) and is priced 50 percent higher than Zosyn/Tazocin would earn a higher patient share in the U.S. (50 percent) than in Europe (30 percent) for the treatment of hospital-acquired pneumonia. This is due to infectious disease specialists in Europe being more sensitive to pricing in their prescribing decisions.

The new report entitled Hospital-Acquired Pneumonia: Resistance Concerns Create Opportunities for New Broad-Spectrum Antibiotics also finds that Merck's Primaxin will remain Decision Resources' proprietary clinical gold standard through 2017. While some therapies in development for hospital-acquired pneumonia hold promise, most have efficacy, safety and tolerability and/or delivery issues when compared to Primaxin.

"Interviewed thought leaders believe that Primaxin has a better spectrum of activity than the benchmark therapy, Zosyn/Tazocin and perceive the agent to be more active against ESBL-producing E. coli and Klebsiella pneumoniae, Pseudomonas and Acinetobacter," stated Hemali Patel, Ph.D., analyst at Decision Resources. "Prescribers we surveyed agree that Primaxin is the most effective antibiotic for hospital-acquired pneumonia."

About the Report

Hospital-Acquired Pneumonia: Resistance Concerns Create Opportunities for New Broad-Spectrum Antibiotics is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Antibiotic Combo Fights Resistant TB
2. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
3. Antibiotic-Resistant Meningitis Reported in U.S.
4. Health experts urge supermarket pharmacies to get smart about free antibiotics
5. Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia
6. Could carbon dioxide replace antibiotics in surgery?
7. Study shows rise in antibiotic resistant pediatric head and neck infections
8. Free antibiotics: The wrong prescription for cold and flu season
9. E. coli persists against antibiotics through HipA-induced dormancy
10. Antibiotics as Loss Leaders?
11. Preventive Use of Antibiotics Cuts ICU Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... Wine Tasting Event in New York City, with long-time partners The Paul Foundation, ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace is ... styles with unique displacement design elements," said Christina Austin - CEO of Pixel ... from a variety of design styles that include both left aligned and right ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... will speak at the American Conference Institute’s 21st Drug & Medical Device Litigation ... Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 The U.S. Food ... Jardiance (empagliflozin) to reduce the risk of cardiovascular death ... cardiovascular disease. "Cardiovascular disease is a ... diabetes mellitus," said Jean-Marc Guettier , M.D., C.M., ... in FDA,s Center for Drug Evaluation and Research. "Availability ...
(Date:12/2/2016)... 2, 2016 Persistence Market Research ... its upcoming report titled, "Global Market Study on Cardiac Pacemaker: ... of -1.4% between 2016 and 2024". The global cardiac pacemaker ... and this is likely to decline to US$ 3923.8 ... cardiac pacemaker market is anticipated to exhibit a declining ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Market Research titled "Global Market Study on Automated Endoscope Reprocessors: ... Register a CAGR of 8.6% Between 2016 and 2024 " the ... 2015 and is expected to expand at a CAGR of ... market valuation of US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology: